Physician profile
Stephanie Baxter
NPI 1003076530
$1,351.37
in general payments reported to CMS, 2019-2025
15 companies · $78.79 in 2025
The $78.79 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $343 · 2021: $133 · 2022: $243 · 2023: $38.59 · 2024: $273 · 2025: $78.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $305.70 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $211.39 | 2020 | |
| Coopervision INC. | $156.86 | 2019-2023 | Onefit Contact Lens |
| Abbvie INC. | $119.46 | 2022 | |
| Quidel Corporation | $113.89 | 2019 | |
| Allergan, INC. | $89.12 | 2019-2021 | |
| Sight Sciences, INC. | $71.35 | 2022-2025 | Tearcare System, Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $66.18 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $53.66 | 2024 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $47.97 | 2019-2024 | |
| Dompe US, INC. | $46.71 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $20.40 | 2025 | |
| Horizon Therapeutics Plc | $18.15 | 2021 | |
| Vantage Technology LLC | $15.89 | 2022 | |
| Abb Con-Cise Optical Group LLC | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.